Search

Your search keyword '"Novavax Inc. -- Licensing agreements"' showing total 47 results
Start Over Descriptor "Novavax Inc. -- Licensing agreements"
47 results on '"Novavax Inc. -- Licensing agreements"'

1. Novavax, Sanofi enter licensing agreement to co-commercialize Covid-19 vaccine and develop novel Covid-19-influenza combination vaccines

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has entered into a co-exclusive licensing agreement with Sanofi. The terms of the agreement include: a co-exclusive license [...]

Published
2024

2. Client Novavax, Maker of COVID-19 Vaccine, Signs $1.4 Billion Agreement with Sanofi

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Influenza vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

Massachusetts: Ropes & Gray has issued the following press release: Ropes & Gray represented Novavax Inc., in a co-exclusive licensing agreement with French pharmaceutical company Sanofi to sell Novavax COVID-19 [...]

Published
2024

3. NOVAVAX AND SANOFI ANNOUNCE CO-EXCLUSIVE LICENSING AGREEMENT TO CO-COMMERCIALIZE COVID-19 VACCINE AND DEVELOP NOVEL COVID-19-INFLUENZA COMBINATION VACCINES

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, News, opinion and commentary
Abstract

GAITHERSBURG, Md. -- The following information was released by Novavax, Inc.: Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 [...]

Published
2024

4. Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Provides Novavax with cash and an equity investment totalling approximately [...]

Published
2024

5. Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines - Agreement provides patients with broader access to [...]

Published
2024

6. Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine [...]

Published
2024

7. Sanofi and Novavax sign co-exclusive licensing agreement

Subjects
Novavax Inc. -- Licensing agreements, Euronext Paris S.A. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Health care industry -- Licensing agreements, Securities industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Health care industry, Securities industry, Company licensing agreement, Business
Abstract

M2 EQUITYBITES-May 10, 2024-Sanofi and Novavax sign co-exclusive licensing agreement (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Novavax Inc (Nasdaq:NVAX) announced [...]

Published
2024

8. Sanofi and Novavax sign co-exclusive licensing agreement

Subjects
Novavax Inc. -- Licensing agreements, Euronext Paris S.A. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Health care industry -- Licensing agreements, Securities industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Health care industry, Securities industry, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-May 10, 2024-Sanofi and Novavax sign co-exclusive licensing agreement (C)2024 M2 COMMUNICATIONS French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Novavax Inc (Nasdaq:NVAX) announced on [...]

Published
2024

9. NOVAVAX'S UPDATED COVID-19 VACCINE RECEIVES EMERGENCY USE AUTHORIZATION IN THE REPUBLIC OF KOREA

Subjects
Novavax Inc. -- Licensing agreements, Vaccination, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Company licensing agreement, News, opinion and commentary
Abstract

GAITHERSBURG, Md. -- The following information was released by Novavax, Inc.: Novavaxá'sá partner, áSK bioscience,átoday announced that áNovavax's updated COVID-19 vaccine (NVX-CoV2601) has received Emergency Use Authorization áfromá the Ministry [...]

Published
2023

10. Novavax: Nuvaxovid Approved in South Korea for COVID-19 Active Immunization Booster

Subjects
Novavax Inc. -- Licensing agreements, Immunization, Biotechnology industry -- Licensing agreements, Drug approval, Vaccines -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary, Nuvaxovid (Vaccine) -- Licensing agreements
Abstract

Novavax, Inc. (NVAX) said its partner SK bioscience has received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid for use as a [...]

Published
2023

11. Novavax, Serum Institute collaborate to develop and commercialise NVX CoV2373, COVID-19 vaccine candidate

Subjects
Novavax Inc. -- Licensing agreements, Vaccines -- Licensing agreements, Recombinant proteins, Pharmaceutical industry -- Licensing agreements, COVID-19, Company licensing agreement, Pharmaceuticals and cosmetics industries, Coalition for Epidemic Preparedness Innovations
Abstract

Byline: Our Bureau Novavax, Inc. a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases has inked a license agreement with Serum Institute of India to develop and commercialize [...]

Published
2020

12. Novavax and SK bioscience Expand Manufacturing Agreement

Subjects
Novavax Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Company licensing agreement, Business, international
Abstract

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK [...]

Published
2021

13. Novavax and SK bioscience Expand Manufacturing Agreement

Subjects
Novavax Inc. -- Licensing agreements, Vaccines -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

GAITHERSBURG: Novavax, Inc has issued the following news release: Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, [...]

Published
2021

14. NOVAVAX AND SK BIOSCIENCE EXPAND MANUFACTURING AGREEMENT

Subjects
Novavax Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Antigens, Vaccines -- Licensing agreements, Company licensing agreement, News, opinion and commentary
Abstract

GAITHERSBURG, Md. -- The following information was released by Novavax, Inc.: - Novavax secures additional manufacturing capacity through 2022 - SK bioscience secures long-term license to supply NVX-CoV2373 for the [...]

Published
2021

15. Serum Institute's Covovax Anticipated Launch By September, Says CEO Adar Poonawalla

Subjects
Novavax Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international, Law
Abstract

Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of Covid-19 vaccine Covovax have begun in India and the company hopes to launch it by September [...]

Published
2021

16. Covovax trials begin in India, hope to launch it by Sept 2021: Adar Poonawalla

Subjects
Novavax Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international, Law
Abstract

Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of Covid-19 vaccine Covovax have begun in India and the company hopes to launch it by September [...]

Published
2021

17. Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea

Subjects
Novavax Inc. -- Licensing agreements, BioScience Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Existing partnership for manufacture of NVX-CoV2373 expanded to increase production capacity and supply vaccine to the Korean Government GAITHERSBURG, Md., Feb. 15, 2021 (GLOBE NEWSWIRE) [...]

Published
2021

18. NOVAVAX ANNOUNCES EXPANDED COLLABORATION AND LICENSE AGREEMENT WITH SK BIOSCIENCE FOR 40 MILLION DOSES OF COVID-19 VACCINE FOR SOUTH KOREA

Subjects
Novavax Inc. -- Licensing agreements, BioScience Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, News, opinion and commentary
Abstract

GAITHERSBURG, Md. -- The following information was released by Novavax, Inc.: Existing partnership for manufacture of NVX-CoV2373 expanded to increase production capacity and supply vaccine to the Korean Government GAITHERSBURG, [...]

Published
2021

19. Novavax expands collaboration and license agreement with SK bioscience, Co. Limited for NVX-CoV2373

Subjects
Novavax Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-December 24, 2021-Novavax expands collaboration and license agreement with SK bioscience, Co. Limited for NVX-CoV2373 (C)2021 M2 COMMUNICATIONS Novavax, Inc. (Nasdaq: NVAX), a biotechnology company, announced on Thursday that [...]

Published
2021

20. Novavax expands collaboration and license agreement with SK bioscience, Co. Limited for NVX-CoV2373

Subjects
Novavax Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Company licensing agreement, Business
Abstract

M2 EQUITYBITES-December 24, 2021-Novavax expands collaboration and license agreement with SK bioscience, Co. Limited for NVX-CoV2373 (C)2021 M2 COMMUNICATIONS http://www.m2.com Novavax, Inc. (Nasdaq: NVAX), a biotechnology company, announced on Thursday [...]

Published
2021

21. Novavax and Serum Institute of India Announce Development and Commercial Collaboration

Subjects
Novavax Inc. -- Licensing agreements, Vaccines -- Licensing agreements, Recombinant proteins, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international, Coalition for Epidemic Preparedness Innovations
Abstract

(GlobeNewswire) - Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a license agreement with Serum Institute of India Private Limited (SIIPL) [...]

Published
2020

22. Novavax and Serum Institute of India Announce Development and Commercial Collaboration

Subjects
Novavax Inc. -- Licensing agreements, Vaccines -- Licensing agreements, Recombinant proteins, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international, Law, Coalition for Epidemic Preparedness Innovations
Abstract

(GlobeNewswire) - Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a license agreement with Serum Institute of India Private Limited (SIIPL) [...]

Published
2020

23. Serum Institute collaborates with Novavax for malaria vaccine

Subjects
Novavax Inc. -- Licensing agreements, Antigens, Vaccines -- Licensing agreements, Malaria vaccines -- Licensing agreements, Malaria, Pharmaceutical industry -- Licensing agreements, Immune response, Plasmodium falciparum, Clinical trials, Communicable diseases, Biotechnology industries, Diseases, Company licensing agreement, Biotechnology industry, University of Oxford
Abstract

NovavaxÇÖ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University US based Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for [...]

Published
2020

24. Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Subjects
Novavax Inc. -- Licensing agreements, Antigens, Vaccines -- Licensing agreements, Malaria vaccines -- Licensing agreements, Medical research, Malaria, Pharmaceutical industry -- Licensing agreements, Immune response, Plasmodium falciparum, Communicable diseases, Biotechnology industries, Diseases, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

GAITHERSBURG, Mar 11, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Novavax' proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University -- Phase [...]

Published
2020

25. Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Subjects
Novavax Inc. -- Licensing agreements, Antigens, Vaccines -- Licensing agreements, Malaria vaccines -- Licensing agreements, Medical research, Malaria, Pharmaceutical industry -- Licensing agreements, Immune response, Communicable diseases, Biotechnology industries, Diseases, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - Novavax' proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University - Phase 2b clinical efficacy study [...]

Published
2020

26. Biotech firm inks deal

Author

Graham, Scott

Subjects
Novavax Inc. -- Licensing agreements, SmithKline Beecham Corp. -- Licensing agreements, Biological products industry -- Licensing agreements, Biological products -- Licensing agreements, Company licensing agreement, Business, Economics, Business, regional
Abstract

Columbia-based Novavax Inc., a biopharmaceutical company, has licensed its Hepatitis E vaccine technology to pharmaceutical manufacturer SmithKline Beecham for the development of a human vaccine. Terms of the deal were [...]

Published
2000

27. Novavax gets national buyer for flu shot drug

Author

Werner, Ben

Subjects
Novavax Inc. -- Licensing agreements, Parkedale Pharmaceuticals -- Licensing agreements, Biological products industry -- Licensing agreements, Vaccines -- Licensing agreements, Company licensing agreement, Business, Economics, Business, regional
Abstract

Columbia-based Novavax Inc. is licensing one of its influenza vaccine helpers to national drug company Parkedale Pharmaceuticals. Novavax's Novasome, a so-called 'helper drug' that makes a flu vaccine more effective, [...]

Published
1999

28. Rockville-based Novavax Inc. signs non-exclusive, worldwide license agreement with Wyeth

Subjects
Novavax Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, Business, regional
Abstract

Byline: Daily Record Staff & Wire Reports Novavax Inc. has signed a non-exclusive, worldwide license agreement with Wyeth to obtain rights to a patent application covering virus-like particle (VLP) technology [...]

Published
2007

29. Novavax signs agreement with LG Life Sciences for Influenza vaccines

Subjects
Novavax Inc. -- Licensing agreements, LG Life Sciences Ltd. -- Licensing agreements, Biological products industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business, general
Abstract

Mar 04, 2011 (Datamonitor Financial Deals Tracker via COMTEX) -- Novavax, Inc., a US-based biotechnology company that develops vaccines for infectious diseases, has signed a licensing agreement with LG Life [...]

Published
2011

30. Novavax signs agreement with Life Sciences for Influenza vaccines

Subjects
Novavax Inc. -- Licensing agreements, LG Life Sciences Ltd. -- Licensing agreements, Biological products industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business, general
Abstract

Mar 01, 2011 (Datamonitor Financial Deals Tracker via COMTEX) -- Novavax, Inc., a US-based biotechnology company that develops vaccines for infectious diseases, has signed a licensing agreement with LG Life [...]

Published
2011

31. Novavax terminates license agreement with Laboratorios Farmaceuticos ROVI for Virus-like-particle vaccine technology

Subjects
Novavax Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business, general
Abstract

Feb 11, 2010 (Datamonitor Financial Deals Tracker via COMTEX) -- Novavax, Inc., a US-based biotechnology company, has decided to discontinue its negotiations with Laboratorios Farmaceuticos ROVI, S.A., a Spain-based chemo-pharmaceutical [...]

Published
2010

32. Novavax terminates license agreement with Laboratorios Farmaceuticos ROVI

Subjects
Novavax Inc. -- Licensing agreements, Vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business, general
Abstract

Feb 08, 2010 (Datamonitor Financial Deals Tracker via COMTEX) -- Novavax, Inc. has announced today that it has decided to discontinue negotiations in its pursuit of the previously announced collaboration [...]

Published
2010

33. IGI and Novavax enter into license agreement

Subjects
Novavax Inc. -- Licensing agreements, IGI Inc. -- Licensing agreements, Bharat Biotech International Ltd. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

BUENA, N.J. -- IGI, INC, (AMEX:IG) announced today that Novavax, Inc. (Nasdaq - 'NVAX') and IGI have entered into an agreement that would expand Novavax's existing strategic alliance with Bharat [...]

Published
2007

34. Novavax Completes ESTRASORB Partnership

Subjects
Novavax Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

MALVERN, Pa., Oct. 18 /PRNewswire-FirstCall/ -- Novavax, Inc. announced today that it has entered into a definitive license and supply agreement on ESTRASORB(R) (estradiol topical emulsion) with Esprit Pharma, a [...]

Published
2005

35. FDA Accepts for Review New Drug Application for Estrasorb(TM), a Topical Estrogen Replacement Therapy Licensed to King Pharmaceuticals

Subjects
Novavax Inc. -- Licensing agreements, Drugs -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

BRISTOL, Tenn., Sept. 5 /PRNewswire/ -- King Pharmaceuticals, Inc. (NYSE: KG) reported today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) [...]

Published
2001

36. Novavax Expands Licensing Agreement With King Pharmaceuticals For ESTRASORB(TM) and ANDROSORB(TM)

Subjects
Novavax Inc. -- Licensing agreements, Drugs -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

- Novavax Receives $3 Million in Licensing Fees, Rights to $3 Million in Milestone Payments and Royalties on Future Sales - COLUMBIA, Md., June 29 /PRNewswire/ -- NOVAVAX, INC. (Amex: [...]

Published
2001

37. Novavax Submits New Drug Application for ESTRASORB(TM), A Topical Estrogen Replacement Therapy Licensed to King

Subjects
Novavax Inc. -- Licensing agreements, Drugs -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

King's Exclusive License for ESTRASORB(TM) is Expanded to Include Canada and Remainder of Europe BRISTOL, Tenn., June 29 /PRNewswire/ -- King Pharmaceuticals, Inc. (NYSE: KG) reported that Novavax, Inc. (Amex: [...]

Published
2001

38. King Pharmaceuticals Announces Exclusive License for Estrasorb(TM) with Novavax

Subjects
Novavax Inc. -- Licensing agreements, Drugs -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

BRISTOL, Tenn., Jan. 8 /PRNewswire/ -- King Pharmaceuticals, Inc. (NYSE: KG) announced today that it has obtained an exclusive license from Novavax, Inc. (Amex: NOX) to promote, market, distribute and [...]

Published
2001

39. King Pharmaceuticals Announces Exclusive License For HPV Vaccines With Novavax

Subjects
Novavax Inc. -- Licensing agreements, Drugs -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

BRISTOL, Tenn., Dec. 20 /PRNewswire/ -- King Pharmaceuticals, Inc. (NYSE: KG) announced today that it has obtained an exclusive license from Novavax, Inc. (Amex: NOX) to use its proprietary cell [...]

Published
2000

40. Novavax Co-Invented Hepatitis E Vaccine Technology Licensed to SmithKline Beecham

Subjects
Novavax Inc. -- Licensing agreements, SmithKline Beecham PLC -- Licensing agreements, Drugs -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Columbia, MD, Sept. 14 /PRNewswire/ -- Novavax, Inc. (Amex: NOX) today announced that the National Institutes of Health (NIH) recently licensed the rights to the NIH and Novavax recombinant Hepatitis [...]

Published
2000

41. Novavax Enters Licensing Option Agreement on New Anti-Infectives For the Treatment of Bacterial and Parasitic Infections

Subjects
Novavax Inc. -- Licensing agreements, Drugs -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

COLUMBIA, Md., May 4 /PRNewswire/ -- Novavax, Inc. (Amex: NOX) today announced it has entered into a licensing option agreement with California Pacific Medical Center and St. Mary's Medical Center [...]

Published
2000

42. Novavax Licenses a Series of Novasome(R) Adjuvants to Parkedale Pharmaceuticals for Use With Fluogen(R) Influenza Vaccines

Subjects
Novavax Inc. -- Licensing agreements, King Pharmaceuticals Inc. -- Licensing agreements, Parkedale Pharmaceuticals -- Licensing agreements, Drugs -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

- Data Recently Presented at the 50th Annual Meeting of the Society for Industrial Microbiology - COLUMBIA, Md., Oct. 22 /PRNewswire/ -- Novavax, Inc. (Amex: NOX) today announced that it [...]

Published
1999

43. Novavax licenses VLP from Wyeth

Subjects
Novavax Inc. -- Licensing agreements, Wyeth -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

US infectious disease specialist Novavax has signed a non-exclusive worldwide licensing agreement with Wyeth, under which it gains rights to the latter's patent application covering the use of its virus-like [...]

Published
2007

44. IGI and Novavax enter into license agreement

Subjects
Novavax Inc. -- Licensing agreements, IGI Inc. -- Licensing agreements, Bharat Biotech International Ltd. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Health
Abstract

IGI, Inc., (IG) announced that Novavax, Inc., (NVAX) and IGI have entered into an agreement that would expand Novavax's existing strategic alliance with Bharat Biotech International, Ltd., of India. Under [...]

Published
2007

45. Novavax to reacquire all rights to Estrasorb

Subjects
Novavax Inc. -- Licensing agreements, King Pharmaceuticals Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

Novavax and King Pharmaceuticals have agreed to end their co-promotion agreement for Estrasorb (estradiol topical emulsion), enabling Novavax to reaquire all worldwide rights to the product. In addition, the latter [...]

Published
2004

46. King Pharmaceuticals announces exclusive license for papillomavirus vaccines with Novavax

Subjects
Novavax Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Antineoplastic agents -- Licensing agreements, Vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Antimitotic agents -- Licensing agreements, Company licensing agreement, Biotechnology industry, Business
Abstract

King Pharmaceuticals, Inc. (Bristol, TN; 423-989-8077) announced that it has obtained an exclusive license from Novavax, Inc. (301-854-3900) to use its proprietary cell line to develop and potentially commercialize recombinant [...]

Published
2000

47. Novavax co-invented hepatitis E vaccine technology licensed to SmithKline Beecham

Subjects
Novavax Inc. -- Licensing agreements, SmithKline Beecham PLC -- Licensing agreements, Biological products industry -- Licensing agreements, Virus research, Company licensing agreement, Biotechnology industry, Business
Abstract

Novavax, Inc. (Columbia, MD; 301-854-3900) announced that the National Institutes of Health recently licensed the rights to the NIH and Novavax recombinant Hepatitis E virus clones and antigen production technology [...]

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results